E2F4 over-expression was associated with breast and colon cancers; its mutation was associated with endometrial, prostate, colorectal, gastric, and ulcerative colitis-associated neoplasm; and its amplification was associated with bladder cancer [47–49]. This evidence concerns the gene E2F4 and malignant colon neoplasm.